SWM
VKTX icon

Spire Wealth Management’s Viking Therapeutics VKTX Stock Holding History

Spire Wealth Management’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.33K Buy
+34
New +$1.1K ﹤0.01% 2089
2025
Q1 		– Sell
-175
Closed -$7.04K – 2583
2024
Q4 		$7.04K Buy
+175
New +$9.98K ﹤0.01% 1952
2024
Q2 		– Sell
-740
Closed -$60.7K – 2399
2024
Q1 		$60.7K Buy
+740
New +$32.9K ﹤0.01% 1150
2021
Q2 		– Sell
-301
Closed -$2K – 2975
2021
Q1 		$2K Buy
+301
New +$2.12K ﹤0.01% 2892

Other funds holding VKTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Spire Wealth Management's VKTX Position: Q2 2026 in Review

Spire Wealth Management opened a new position in Viking Therapeutics (VKTX) in Q2 2026: 34 shares worth $1.33K. The stake represents ﹤0.01% of the portfolio and ranks #2089 among its holdings. This is a return to the name: Spire Wealth Management previously reported a position in VKTX as recently as Q4 2024.

Spire Wealth Management first reported a position in VKTX in Q1 2021 and has held it in 4 quarters since. The position peaked at $60.7K in Q1 2024. 436 funds tracked by Wall St. Rank hold VKTX as of Q2 2026.

  • Spire Wealth Management held 34 shares of Viking Therapeutics worth $1.33K as of Q2 2026.
  • Viking Therapeutics was a new Spire Wealth Management position in Q2 2026.
  • Viking Therapeutics made up ﹤0.01% of Spire Wealth Management's portfolio in Q2 2026, its #2089 holding.
  • Spire Wealth Management first reported a position in Viking Therapeutics in Q1 2021 and has held it in 4 quarters since.
  • Spire Wealth Management's Viking Therapeutics position peaked at $60.7K in Q1 2024.
  • 436 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2026.

Based on Spire Wealth Management's 13F filing for Q2 2026, filed 15 Jul 2026.